1. Fourth-quarter sales for fiscal year 2023 grew 5.6 percent, according to a news release. The results come from strong performances in cardiovascular, medical-surgical and neuroscience business, Medtronic said.
2. Full-year sales were down 1.4 percent, which the company said was a result of “continued unfavorable macroeconomic impact of foreign currency translation and inflation.”
3. Medtronic’s neuroscience portfolio saw $2.4 billion in sales in the fourth quarter, a 4.8 percent year-over-year increase. Cranial and spinal technologies saw a 2.8 percent increase year over year with $1.2 billion in revenue.
4. Medtronic projects its fiscal year 2024 sales to grow 4 percent to 4.5 percent.
5. The company also said it plans to acquire EOFlow, a company known for its EO Patch for insulin delivery.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
